Copyright ©The Author(s) 2021.
World J Hepatol. Mar 27, 2021; 13(3): 375-383
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.375
Table 1 Characteristics of the included studies
Study design
Follow-up period
Sample size
Donor type
Mean age
Concurrent therapy
Alloway et al[11]2014United StatesPhase-II, 3-sequence, open-label, multicenter, prospective study1 yr59NR49.8Mycophenolate mofetil
Kim et al[13]2016South Korea2-armed, parallel group, prospective, randomized, open-label, phase IV1 yr79Deceased54NR
Sańko-Resmer et al[14]2012United KingdomMulticentre, open-label, single-sequence, crossover, phase IIIb 3 mo98NR55None
Shin et al[17]2018South KoreaPhase IV, randomized, open-label, comparative, single-center study6 mo100NR52Corticosteroid, mycophenolate mofetil, and basiliximab.
Trunečka et al[15]201016 countries1:1-randomized, double-blind, double-dummy, two-arm, parallel-group phase III, comparative study1 yr471NR52Mycophenolate sodium
DuBay et al[12]2019United StatesPhase II, open label, multicenter, randomized trial1 yr29Deceased54.4Mycophenolate mofetil, mycophenolic acid sodium, prednisone, or azathioprine
Fischer et al[16]2010GermanyRandomized, phase II, multicenter, open-label, prospective trial6 wk129NR47Anti-fungal, antibiotics, anti-hypertensives, antiepileptics and rifampicin)